ALPINE IMMUNE SCIENCES, INC.
ALPINE IMMUNE SCIENCES, INC. (ALPN): 4 pipeline candidates · ~32 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
31.7 months
D/E 0.12 · 0% dilution
Lead: Phase 2
4 candidates
N/A
N/A
A transparent, data-derived signal for ALPINE IMMUNE SCIENCES, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$33.3M
Quarterly Burn
$27.7M
Runway
31.7 mo
Revenue
$7.0M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| alpn-101 | Phase 2 |
| alpn-202 | Preclinical |
| alpn-303 | Phase 1/Phase 2 |
| povetacicept | Phase 1/Phase 2 |
Frequently asked questions
How many drug candidates are in ALPINE IMMUNE SCIENCES, INC.'s pipeline?
ALPINE IMMUNE SCIENCES, INC. (ALPN) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is ALPINE IMMUNE SCIENCES, INC.'s lead drug candidate?
ALPINE IMMUNE SCIENCES, INC.'s most advanced tracked candidate is alpn-101 (Phase 2) for systemic lupus erythematosus.
What is ALPINE IMMUNE SCIENCES, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, ALPINE IMMUNE SCIENCES, INC. has approximately 31.7 months of cash runway.
Who is the CEO of ALPINE IMMUNE SCIENCES, INC.?
Mitchell H. Gold, M.D. is the chief executive officer of ALPINE IMMUNE SCIENCES, INC. (ALPN).
Get the full picture on ALPINE IMMUNE SCIENCES, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.